• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Occupational Diseases and Environmental Medicine >Potential Toxic Effects of Olanzapine on Metabolic Parameters in &i&de Novo&/i& Paranoid Schizophrenic Patients. The Role of Adjunctive Aripeprazole: Clinical and Experimental Study
【24h】

Potential Toxic Effects of Olanzapine on Metabolic Parameters in &i&de Novo&/i& Paranoid Schizophrenic Patients. The Role of Adjunctive Aripeprazole: Clinical and Experimental Study

机译：奥氮平对de novo / i中代谢参数的潜在毒性作用。偏执型精神分裂症患者。辅助阿立哌唑的作用：临床和实验研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Approximately 75% of all deaths in people with schizophrenia are caused by physical illness with cardiovascular disease [CVD] being the commonest cause of death. Factors predisposing people with schizophrenia to CVD include antipsychotic medication. Aim of Work: The aim of this study was to detect metabolic syndrome and its components in de novo paranoid schizophrenics on olanzapine therapy and the metabolic benefits of addition of aripeprazole, clinically and experimentally. Methodology: 1) Clinical study: 200 Outpatients suffered from de novo paranoid schizophrenia according to 10~(th) International Classification of Psychiatric Disorders, Research Criteria [ICD10 RC] were included in the study. None of them had any component of metabolic syndrome. They were maintained on olanzapine [10 - 20 mg]. Patients were assessed clinically, psychometrically using Scale for the Assessment of Negative [SANS] and Positive [SAPS] Symptoms and metabolically at base line and after 6 months. Patients who had metabolic syndrome after 6 month of starting olanzapine therapy, were randomly divided into two groups according to added regime to maintained olanzapine: Group 1: olanzapine [10 mg/day] + placebo [empty hard gelatin capsule]. Group II: olanzapine [10 mg/day] + aripeprazole [10 mg/day]. 2) Experimental study: 40 male albino rats were randomly equally divided into 4 groups: Group 1 [control group]: received a standard diet, Group II [olanzapine treated]: received olanzapine at a dose of 0.5 mg/kg/day, Group III [aripiprazole treatd]: received aripiprazole at a dose of 2 mg/kg/day, Group IV [combined olanzapine and aripiprazole treated]: received olanzapine at a dose of 0.5 mg/kg/day combined with aripiprazole at a dose of 2 mg/kg/day orally. The duration of the study was 16 weeks. All treated rat groups were assessed for metabolic parameters, liver enzymes and histopathology. Results: Clinically, after the 6 months of olanzapine treatment [mean dose 12.75 mg], there was significant increase [p < 0.001] in weight, body mass index, triglyceride, total cholesterol, and fasting blood glucose level compared to base line level of these parameters (Table 1). 32 patients [16%] suffered from metabolic syndrome after 6 months of olanzapine therapy. After 3 months of aripeprazole, [10 mg/day], addition to maintained olanzapine therapy to patients suffered from metabolic syndrome, there was significant [p < 0.001] improvement in tested parameters (Table 2). Experimentally, the rats in group II [olanzapine treated rats] had significantly higher body weight [p = 0.002], liver weight [p < 0.001], metabolic parameters [p < 0.001] and liver enzymes [p < 0.001] than controls. Group 1v [combined olanzapine and aripeprazole treated rats] had significant decrease in metabolic parameters and liver enzymes in comparison to olanzapine treated rats (Table 3). Histopathologically, liver fat cells were significantly [p < 0.001] present in the olanzapine-only [8 rats] treatment group compared to group 1v [3 rats] and group 11 [zero]. Liver fat cells were higher in number and larger in size in group 1 compared to group 1v and group 1. Conclusion and Recommendation: Olanzapine treatment was found to be associated with risk factors of metabolic syndrome clinically and experimentally and its hepatic manifestation of non-alcoholic fatty liver disease in wister rats. Improvements were observed clinically and experimentally in metabolic measures, liver enzymes and liver histopathology by addition of aripeprazole. Patients on olanzapine therapy must be followed regularly regarding metabolic parameters, hepatic, cardiac and cerebrovascular morbidity, with urgent interference with early manifestations. It is recommended to check liver enzymes regularly for those patients kept on atypical antipsychotic drug [olanzapine].
机译：背景：精神分裂症患者中约有75％的死亡是由身体疾病引起的，心血管疾病[CVD]是最常见的死亡原因。精神分裂症患者易患CVD的因素包括抗精神病药。工作目的：本研究的目的是在临床和实验上检测奥氮平治疗的从头偏执型精神分裂症患者的代谢综合症及其成分，以及添加阿立哌唑的代谢益处。方法：1）临床研究：根据国际精神病学分类（第10版），研究标准[ICD10 RC]，对200例从头患有偏执型精神分裂症的门诊患者进行了研究。他们都没有代谢综合征的任何成分。他们维持在奥氮平[10-20 mg]上。使用量表对患者进行临床，心理计量学评估，以评估阴性[SANS]和阳性[SAPS]症状，并在基线和6个月后进行代谢评估。在开始使用奥氮平治疗6个月后患有代谢综合征的患者，根据维持奥氮平的添加方案随机分为两组：第1组：奥氮平[10 mg /天] +安慰剂[空硬明胶胶囊]。第二组：奥氮平[10 mg /天] +阿立哌唑[10 mg /天]。 2）实验研究：40只雄性白化病大鼠随机分为4组：第1组[对照组]：接受标准饮食，第II组[经奥氮平治疗]：接受0.5 mg / kg /天的奥氮平，组III [阿立哌唑治疗]：接受阿立哌唑，剂量为2 mg / kg /天，IV组[奥氮平与阿立哌唑联合治疗]：接受奥氮平，剂量为0.5 mg / kg / day，与阿立哌唑联合，剂量为2 mg / kg /天口服。研究持续时间为16周。评估所有治疗的大鼠组的代谢参数，肝酶和组织病理学。结果：在临床上，奥氮平治疗6个月[平均剂量12.75 mg]后，体重，体重指数，甘油三酸酯，总胆固醇和空腹血糖水平与奥氮平的基线水平相比有显着增加[p <0.001]这些参数（表1）。奥氮平治疗6个月后有32例[16％]患有代谢综合征。阿立哌唑[10 mg /天] 3个月后，除了对患有代谢综合征的患者进行奥氮平维持治疗外，测试参数也有显着[p <0.001]改善（表2）。实验上，第二组的大鼠[奥氮平治疗的大鼠]的体重[p = 0.002]，肝脏的重量[p <0.001]，代谢参数[p <0.001]和肝酶[p <0.001]明显高于对照组。与奥氮平治疗的大鼠相比，第1v组[奥氮平和阿立哌唑联合治疗的大鼠]的代谢参数和肝酶显着降低（表3）。在组织病理学上，与仅1o组[3只大鼠]和11组[0]相比，仅奥氮平[8只]治疗组中肝脂肪细胞显着[p <0.001]。与第1v组和第1组相比，第1组中的肝脂肪细胞数量更多，体积更大。结论和建议：奥氮平治疗被发现与临床和实验中代谢综合征的危险因素及其非酒精性肝表现有关肥胖大鼠的脂肪肝疾病。通过添加阿立哌唑，在代谢指标，肝酶和肝组织病理学方面在临床和实验上均得到了改善。必须定期随访接受奥氮平治疗的患者的代谢参数，肝，心脏和脑血管发病率，并紧急干预早期表现。对于那些服用非典型抗精神病药[奥氮平]的患者，建议定期检查肝酶。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号